The first phase of "recombinant human tumor necrosis factor related apoptosis inducing ligand for injection" was completed

On March 24, humanwell said at the 2013 performance presentation meeting that the first class new drug "recombinant human tumor necrosis factor related apoptosis inducing ligand for injection" of Shenzhen Xinpeng Bioengineering Co., Ltd., a wholly-owned subsidiary of the company, has completed the first phase of clinical application and is applying for the second phase of clinical approval According to Xinpeng biology official website, the "recombinant human tumor necrosis factor related apoptosis inducing ligand" project under research of the company has been listed as a major national science and technology special project in the 15th and 12th Five Year Plan, supported by the national "863" project If the research and development of the specific genetic engineering anti-cancer drug is successful, it will bring a new revolution to cancer treatment It is expected that after the product is put on the market, the new annual sales volume will be More than 200 million yuan According to the information on the website of the State Food and drug administration, Xinpeng bio applied for the above new anticancer drugs as early as 2008, and was approved for clinical application in April 2010, but has not yet applied for production Another Haizheng pharmaceutical company in China, which is developing the drug, recently said publicly that the clinical research of products with similar mechanism of action at home and abroad is relatively stagnant, so the company suspended the research and development of the product.